Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China. more
Time Frame | CASI | Sector | S&P500 |
---|---|---|---|
1-Week Return | -20.87% | 0.31% | -1.26% |
1-Month Return | -19.37% | 0.6% | -4.16% |
3-Month Return | -56.36% | -9.44% | -0.46% |
6-Month Return | -59.36% | -5.15% | 3.58% |
1-Year Return | -52.88% | 0.33% | 22.47% |
3-Year Return | -64.85% | 4.53% | 25.13% |
5-Year Return | -92.3% | 35.98% | 77.7% |
10-Year Return | -84.97% | 100.72% | 190.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 4.13M | 15.14M | 30.17M | 43.11M | 33.88M | [{"date":"2019-12-31","value":9.58,"profit":true},{"date":"2020-12-31","value":35.12,"profit":true},{"date":"2021-12-31","value":69.98,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":78.59,"profit":true}] |
Cost of Revenue | 3.94M | 9.51M | 12.56M | 15.83M | 13.83M | [{"date":"2019-12-31","value":24.86,"profit":true},{"date":"2020-12-31","value":60.07,"profit":true},{"date":"2021-12-31","value":79.34,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":87.36,"profit":true}] |
Gross Profit | 196.00K | 5.63M | 17.61M | 27.28M | 20.05M | [{"date":"2019-12-31","value":0.72,"profit":true},{"date":"2020-12-31","value":20.65,"profit":true},{"date":"2021-12-31","value":64.56,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":73.5,"profit":true}] |
Gross Margin | 4.74% | 37.20% | 58.38% | 63.28% | 59.19% | [{"date":"2019-12-31","value":7.5,"profit":true},{"date":"2020-12-31","value":58.79,"profit":true},{"date":"2021-12-31","value":92.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.53,"profit":true}] |
Operating Expenses | 40.19M | 38.95M | 52.89M | 53.77M | 45.13M | [{"date":"2019-12-31","value":74.74,"profit":true},{"date":"2020-12-31","value":72.43,"profit":true},{"date":"2021-12-31","value":98.37,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.93,"profit":true}] |
Operating Income | (39.99M) | (33.31M) | (35.28M) | (26.49M) | (25.08M) | [{"date":"2019-12-31","value":-3999100000,"profit":false},{"date":"2020-12-31","value":-3331300000,"profit":false},{"date":"2021-12-31","value":-3528200000,"profit":false},{"date":"2022-12-31","value":-2649100000,"profit":false},{"date":"2023-12-31","value":-2508000000,"profit":false}] |
Total Non-Operating Income/Expense | (4.31M) | (13.33M) | (239.00K) | (10.81M) | (598.00K) | [{"date":"2019-12-31","value":-430900000,"profit":false},{"date":"2020-12-31","value":-1333200000,"profit":false},{"date":"2021-12-31","value":-23900000,"profit":false},{"date":"2022-12-31","value":-1081300000,"profit":false},{"date":"2023-12-31","value":-59800000,"profit":false}] |
Pre-Tax Income | (45.36M) | (47.51M) | (35.84M) | (37.43M) | (26.29M) | [{"date":"2019-12-31","value":-4536200000,"profit":false},{"date":"2020-12-31","value":-4751100000,"profit":false},{"date":"2021-12-31","value":-3584200000,"profit":false},{"date":"2022-12-31","value":-3743100000,"profit":false},{"date":"2023-12-31","value":-2629200000,"profit":false}] |
Income Taxes | 6.05M | 15.06M | 1.93M | 1.98M | (81.00K) | [{"date":"2019-12-31","value":40.16,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":12.82,"profit":true},{"date":"2022-12-31","value":13.15,"profit":true},{"date":"2023-12-31","value":-0.54,"profit":false}] |
Income After Taxes | (51.41M) | (62.57M) | (37.77M) | (39.41M) | (26.21M) | [{"date":"2019-12-31","value":-5140800000,"profit":false},{"date":"2020-12-31","value":-6256700000,"profit":false},{"date":"2021-12-31","value":-3777200000,"profit":false},{"date":"2022-12-31","value":-3941100000,"profit":false},{"date":"2023-12-31","value":-2621100000,"profit":false}] |
Income From Continuous Operations | (45.76M) | (47.51M) | (35.93M) | (40.26M) | (26.26M) | [{"date":"2019-12-31","value":-4575700000,"profit":false},{"date":"2020-12-31","value":-4751100000,"profit":false},{"date":"2021-12-31","value":-3593000000,"profit":false},{"date":"2022-12-31","value":-4025700000,"profit":false},{"date":"2023-12-31","value":-2625900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (51.41M) | (62.57M) | (37.77M) | (39.41M) | (26.94M) | [{"date":"2019-12-31","value":-5140800000,"profit":false},{"date":"2020-12-31","value":-6256700000,"profit":false},{"date":"2021-12-31","value":-3777200000,"profit":false},{"date":"2022-12-31","value":-3941100000,"profit":false},{"date":"2023-12-31","value":-2693800000,"profit":false}] |
EPS (Diluted) | (4.70) | (4.20) | (2.70) | (2.98) | (2.02) | [{"date":"2019-12-31","value":-470,"profit":false},{"date":"2020-12-31","value":-420,"profit":false},{"date":"2021-12-31","value":-270,"profit":false},{"date":"2022-12-31","value":-298,"profit":false},{"date":"2023-12-31","value":-202,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CASI | |
---|---|
Cash Ratio | 1.41 |
Current Ratio | 3.20 |
Quick Ratio | 2.32 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CASI | |
---|---|
ROA (LTM) | -26.60% |
ROE (LTM) | -85.43% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CASI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.78 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.22 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CASI | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1.70 |
P/B | 2.84 |
EV/R | 1.71 |
EV/Ebitda | 0.07 |
PEG | NM |
CASI Pharmaceuticals Inc (CASI) share price today is $2.54
Yes, Indians can buy shares of CASI Pharmaceuticals Inc (CASI) on Vested. To buy CASI Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CASI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of CASI Pharmaceuticals Inc (CASI) via the Vested app. You can start investing in CASI Pharmaceuticals Inc (CASI) with a minimum investment of $1.
You can invest in shares of CASI Pharmaceuticals Inc (CASI) via Vested in three simple steps:
The 52-week high price of CASI Pharmaceuticals Inc (CASI) is $8.19. The 52-week low price of CASI Pharmaceuticals Inc (CASI) is $2.05.
The price-to-earnings (P/E) ratio of CASI Pharmaceuticals Inc (CASI) is
The price-to-book (P/B) ratio of CASI Pharmaceuticals Inc (CASI) is 2.84
The dividend yield of CASI Pharmaceuticals Inc (CASI) is 0.00%
The market capitalization of CASI Pharmaceuticals Inc (CASI) is $39.35M
The stock symbol (or ticker) of CASI Pharmaceuticals Inc is CASI